NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease.
NAMPT
NAPRT
anti-TNF
anti-integrins
inflammatory bowel diseases
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
12
2022
accepted:
17
01
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Nicotinamide phosphoribosyltransferase (NAMPT) and nicotinic acid phosphoribosyl transferase (NAPRT) are key intracellular enzymes that participate in the biosynthesis on NAD but have also been shown to be released as proinflammatory cytokines. A number of reports have shown that circulating NAMPT is increased in serum of patients with inflammatory disorders, including inflammatory bowel diseases (IBD), while nothing is known regarding circulating NAPRT and the presence of both cytokines in IBD patient stools. In the present study, we evaluated eNAMPT and eNAPRT levels in a large cohort of IBD patients not on biological therapy and in a subset that then was prescribed biologics. We conducted a retro-perspective study on 180 patients, of which 111 underwent subsequent biological treatment (adalimumab, vedolizumab, and ustekinumab). We analyzed eNAMPT and eNAPRT concentrations in serum and faces of IBD patients, correlating them with response to biologics. We now report that eNAMPT and eNAPRT are significantly increased in both serum and stools of IBD patients. NAMPT and NAPRT levels correlate with disease severity, with C reactive protein and with serum IL-6 levels. Importantly, levels of NAMPT in patients starting treatment with adalimumab correlate with response failure at three months: patients with levels above 4 ng/ml were significantly less likely to obtain benefit. Serum NAMPT as a biomarker of response yields a sensitivity of 91% and a specificity of 100%. The present work strongly suggests that a prospective trial evaluating eNAMPT and eNAPRT levels in relation to response to biologicals in IBD should be initiated.
Sections du résumé
Background
UNASSIGNED
Nicotinamide phosphoribosyltransferase (NAMPT) and nicotinic acid phosphoribosyl transferase (NAPRT) are key intracellular enzymes that participate in the biosynthesis on NAD but have also been shown to be released as proinflammatory cytokines. A number of reports have shown that circulating NAMPT is increased in serum of patients with inflammatory disorders, including inflammatory bowel diseases (IBD), while nothing is known regarding circulating NAPRT and the presence of both cytokines in IBD patient stools. In the present study, we evaluated eNAMPT and eNAPRT levels in a large cohort of IBD patients not on biological therapy and in a subset that then was prescribed biologics.
Methods
UNASSIGNED
We conducted a retro-perspective study on 180 patients, of which 111 underwent subsequent biological treatment (adalimumab, vedolizumab, and ustekinumab). We analyzed eNAMPT and eNAPRT concentrations in serum and faces of IBD patients, correlating them with response to biologics.
Results
UNASSIGNED
We now report that eNAMPT and eNAPRT are significantly increased in both serum and stools of IBD patients. NAMPT and NAPRT levels correlate with disease severity, with C reactive protein and with serum IL-6 levels. Importantly, levels of NAMPT in patients starting treatment with adalimumab correlate with response failure at three months: patients with levels above 4 ng/ml were significantly less likely to obtain benefit. Serum NAMPT as a biomarker of response yields a sensitivity of 91% and a specificity of 100%.
Conclusion
UNASSIGNED
The present work strongly suggests that a prospective trial evaluating eNAMPT and eNAPRT levels in relation to response to biologicals in IBD should be initiated.
Identifiants
pubmed: 36817780
doi: 10.3389/fmed.2023.1116862
pmc: PMC9928959
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1116862Informations de copyright
Copyright © 2023 Colombo, Caviglia, Ravera, Tribocco, Frara, Rosso, Travelli, Genazzani and Ribaldone.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Crohns Colitis. 2020 Jun 19;14(5):694-709
pubmed: 31777929
Pharmaceuticals (Basel). 2022 Jul 10;15(7):
pubmed: 35890147
Minerva Gastroenterol Dietol. 2019 Dec;65(4):298-308
pubmed: 31646851
World J Gastroenterol. 2014 Jun 14;20(22):6912-7
pubmed: 24944482
J Immunol. 2007 Feb 1;178(3):1748-58
pubmed: 17237424
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Eur J Gastroenterol Hepatol. 2016 Jul;28(7):814-9
pubmed: 26934527
PLoS One. 2012;7(4):e35074
pubmed: 22493731
Gastroenterology. 2018 Oct;155(4):1008-1011.e8
pubmed: 29981298
J Clin Lab Anal. 2016 Sep;30(5):552-6
pubmed: 26668098
Pharmaceuticals (Basel). 2022 Jul 12;15(7):
pubmed: 35890155
Nat Commun. 2019 Sep 11;10(1):4116
pubmed: 31511522
Int J Mol Sci. 2019 Jan 04;20(1):
pubmed: 30621173
J Mol Med (Berl). 2020 Apr;98(4):595-612
pubmed: 32338310
J Gastrointestin Liver Dis. 2021 Sep 21;30(3):339-345
pubmed: 34551033
Int J Mol Sci. 2023 Jan 07;24(2):
pubmed: 36674688
Front Oncol. 2020 Mar 19;10:358
pubmed: 32266141
Sci Rep. 2015 Aug 14;5:13135
pubmed: 26272519
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
Nutrition. 2009 Feb;25(2):172-81
pubmed: 18849144
Clin Biochem Rev. 2018 Aug;39(3):77-90
pubmed: 30828114
Pharmacol Res. 2020 Sep;159:104886
pubmed: 32428668
Nat Rev Endocrinol. 2015 Sep;11(9):535-46
pubmed: 26215259
Physiol Res. 2017 Sep 22;66(4):709-714
pubmed: 28406695
Front Immunol. 2019 Jul 25;10:1720
pubmed: 31402913
Cancer Res. 2019 Apr 15;79(8):1938-1951
pubmed: 30777853
J Med Chem. 2017 Mar 9;60(5):1768-1792
pubmed: 28165742
iScience. 2022 Mar 23;25(4):104147
pubmed: 35402885
Eur J Med Chem. 2019 Nov 1;181:111576
pubmed: 31400709